Santhera Pharmaceuticals Holding AG
SANN.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$271.42M
Close$
Share Statistics
| Market cap | $271.42 Million |
|---|---|
| Enterprise Value | $277.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.78 |
| Beta | -0.27 |
| Outstanding Shares | 14,351,000 |
Return
| Return on Equity | 1579.02% |
|---|---|
| Return on Assets | -66.20% |
| Return on Invested Capital | -47.82% |
Valuation & Multiples
| P/E Ratio | -6.26 |
|---|---|
| PEG | 14.05 |
| Price to Sales | 1.46 |
| Price to Book Ratio | -14.58 |
| Enterprise Value to Revenue | 1.84 |
| Enterprise Value to EBIT | -5.86 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | -7.7 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$47.00 M
Average shareholder expectationNext Earnings Call
Expected Date
April 29, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$36.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Santhera Pharmaceuticals Holding AG
78 employees
CEO: Orlando Oliveira Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America...